Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2

Genes and Development

Volumn 14, Issue 13, 2000, Pages 1617-1630

  Giovannini, Marco ^a,b   Robanus Maandag, Els ^b   Van Der Valk, Martin ^b   Niwa Kawakita, Michiko ^a   Abramowski, Vincent ^a   Goutebroze, Laurence ^a   Woodruff, James M ^c   Berns, Anton ^b   Thomas, Gilles ^a  

^a FONDATION JEAN DAUSSET CEPH   (France)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Conditional knockout mice; Cre 1oxP; Neurofibromatosis type 2; Schwann cell tumors; Schwannomin; Tumor suppressor gene

Indexed keywords

ANIMAL TISSUE; ARTICLE; GENE MUTATION; GENETIC SUSCEPTIBILITY; KNOCKOUT MOUSE; MOUSE; NEURILEMOMA; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; SCHWANN CELL;

ALLELES; ANIMALS; BASE SEQUENCE; DNA PRIMERS; EXONS; GENE DELETION; GENES, NEUROFIBROMATOSIS 2; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; NEURILEMMOMA; NEUROFIBROMATOSIS 2; PROMOTER REGIONS (GENETICS);

ANIMALIA; MURINAE;

EID: 0034234894     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Akagi, K., Sandig, V., Vooijs, M., Van der Valk, M., Giovannini, M., Strauss, M., and Berns, A. 1997. Cre-mediated somatic site-specific recombination in mice. Nucleic Acids Res. 25: 1766-1773.
2. Bianchi, A.B., Mitsunaga, S.-I., Cheng, J.Q., Klein, W.M., Jhanwar, S.C., Seizinger, B., Kley, N., Klein-Szanto, A.J.P., and Testa, J.R. 1995. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl. Acad. Sci. 92: 10854-10858.
3. Bolande, R. 1974. The neurochristopathies. A unifying concept of disease arising in neural crest maldevelopment. Hum. Pathol. 5: 409-420.
4. Couly, G.F., Coltey, P.M., and Le Douarin, N.M. 1993. The triple origin of skull in higher vertebrates: A study in quailchick chimeras. Development 117: 409-429.
5. Deguen, B., Merel, P., Goutebroze, L., Giovannini, M., Reggio, H., Arpin, M., and Thomas, G. 1998. Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane. Hum. Mol. Genet. 7:217-226.
6. Eldridge, R. 1981. Central neurofibromatosis with bilateral acoustic neuroma. Adv. Neurol. 29: 57-65.
7. Erlandson, R.A. and Woodruff, J.M. 1982. Peripheral nerve sheath tumors: An electron microscopic study of 43 cases. Cancer 49: 273-287.
8. Giovannini, M., Robanus-Maandag, E., Niwa-Kawakita, M., van der Valk, M., Woodruff, J.M., Goutebroze, L., Merel, P., Berns, A., and Thomas, G. 1999. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes & Dev. 13: 978-986.
9. Gonzalez-Agosti, C., Xu, L., Pinney, D., Beauchamp, R., Hobbs, W., Gusella, J., and Ramesh, V. 1996. The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene 13: 1239-1247.
10. Gu, H., Zou, Y.R., and Rajewsky, K. 1993. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 73: 1155-1164.
11. Gu, H., Marth, J.D., Orban, P.C., Mossmann, H., and Rajewsky, K. 1994. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science 265:103-106.
12. Gutmann, D.H., Sherman, L., Seftor, L., Haipek, C., Hoang Lu, K., and Hendrix, M. 1999. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading. Hum. Mol. Genet. 8: 267-275.
13. Jacks, T. 1996. Tumor suppressor gene mutations in mice. Annu. Rev. Genet. 30: 603-636.
14. Jessen, K.R. and Mirsky, R. 1994. Schwann cell biology. In The neurofibromatoses. A clinical and pathogenetic overview (ed. S.M. Huson and R.A.C. Hughes), pp. 95-134. Chapman & Hall, London, UK.
15. Kaiser-Kupfer, M.I., Freidlin, V., Datiles, M.B., Edwards, P.A., Sherman, J.L., Parry, D., McCain, L.M., and Eldridge, R. 1989. The association of posterior capsular lens opacities with bilateral acoustic neuromas in patients with neurofibromatosis type 2. Arch. Ophthalmol. 107: 541-544.
16. Koga, H., Araki, N., Takeshima, H., Nishi, T., Hirota, T., Kimura, Y., Nakao, M., and Saya, H. 1998. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain. Oncogene 17: 801-810.
17. Lee, M., Brennan, A., Blanchard, A., Zoidl, G., Dong, Z., Tabernero, A., Zoidl, C., Dent, M.A., Jessen, K.R., and Mirsky, R. 1997. P0 is constitutively expressed in the rat neural crest and embryonic nerves and is negatively and positively regulated by axons to generate non-myelin-forming and myelin-forming Schwann cells, respectively. Mol. Cell. Neurosci. 8: 336-350.
18. Lumsden, A.G. 1988. Spatial organization of the epithelium and the role of neural crest cells in the initiation of the mammalian tooth germ. Development 103: 155-169.
19. MacCollin, M. and Gusella, J. 1998. Neurofibromatosis type 2. In The genetic basis of human cancer (ed. B. Vogelstein and K.W. Kinzler), pp. 443-453. McGraw-Hill, USA.
20. Mayfrank, L., Mohadjer, M., and Wullich, B. 1990. Intracranial calcified deposits in neurofibromatosis type 2. A CT study of 11 cases. Neuroradiology 32:33-37.
21. McClatchey, A.I., Saotome, I., Ramesh, V., Gusella, J.F., and Jacks, T. 1997. The NF2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes & Dev, 11: 1253-1265.
22. McClatchey, A.I., Saotome, I., Mercer, K., Crowley, D., Gusella, J.F., Bronson, R.T., and Jacks, T. 1998. Mice heterozygous for a mutation at the NF2 tumor suppressor locus develop a range of highly metastatic tumors. Genes & Dev. 12: 1121-1133.
23. Messing, A., Behringer, R.R., Hammang, J.P., Palmiter, R.D., Brinster, R.L., and Lemke, G. 1992. P0 promoter directs expression of reporter and toxin genes to Schwann cells of transgenic mice. Neuron 8: 507-520.
24. Messing, A., Behringer, R.R., Wrabetz, L., Hammang, J.P., Lemke, G., Palmiter, R.D., and Brinster, R.L. 1994. Hypomyelinating peripheral neuropathies and schwannomas in transgenic mice expressing SV40 T-antigen. J. Neurosci. 14: 3533-3539.
25. Nishi, T., Takeshima, H., Hamada, K., Yoshizato, K., Koga, H., Sato, K., Yamamoto, K., Kitamura, I., Kochi, M., Kuratsu, J.-I., Saya, H., and Ushio, Y. 1997. Neurofibromatosis 2 gene has novel alternative splicings which controls intracellular protein binding. Int. J. Oncology 10: 1025-1029.
26. O'Gorman, S., Dagenais, N.A., Qian, M., and Marchuk, Y. 1997. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc. Natl. Acad. Sci. 94: 14602-14607.
27. Reneker, L.W., Silversides, D.W., Xu, L., and Overbeek, P.A. 2000. Formation of corneal endothelium is essential for anterior segment development: A transgenic mouse model of anterior segment dysgenesis. Development 127: 533-542.
28. Robanus-Maandag, E., Dekker, M., van der Valk, M., Carrozza, M.L., Jeanny, J.C., Dannenberg, J.H., Berns, A., and te Riele, H. 1998. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes & Dev. 12: 1599-1609.
29. Rouleau, G.A., Mérel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C., Plougastel, B. et al. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363: 515-521.
30. Sato, N., Funayama, N., Nagafuchi, A., Yonemura, S., Tsukita, S., and Tsukita, S. 1992. A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites. J. Cell Sci. 103: 131-143.
31. Sekido, Y., Pass, H.I., Bader, S., Mew, D.J.Y., Christman, M.F., Gazdar, A.F., and Minna, J.D. 1995. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 55: 1227-1231.
32. Sterkers, J.M., Perre, J., Viala, P., and Foncin, J.F. 1987. The origin of acoustic neuromas. Acta Otolaryngol. 103: 427-431.
33. Sternberg, N. and Hamilton, D. 1981. Bacteriophage P1 site-specific recombination. I. Recombination between loxP sites. J. Mol. Biol. 150: 467-486.
34. Takeshima, H., Izawa, I., Lee, P.S.Y., Safdar, N., Levin, V.A., and Saya, H. 1994. Detection of cellular proteins that interact with the NF2 tumor suppressor gene product. Oncogene 9: 2135-2144.
35. te Riele, H., Maandag, E.R., and Berns, A. 1992. Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs. Proc. Natl. Acad. Sci. 89: 5128-5132.
36. Topilko, P., Schneider-Maunoury, S., Levi, G., Baron-Van Evercooren, A., Chennoufi, A.B., Seitanidou, T., Babinet, C., and Chamay, P. 1994. Krox-20 controls myelination in the peripheral nervous system. Nature 371: 796-799.
37. Trofatter, J.A., MacCollin, M.M., Rutter, J.L., Murrell, J.R., Duyao, M.P., Parry, D.M., Eldridge, R., Kley, N., Menon, A.G., Pulaski, K. et al. 1993. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72: 791-800.
38. Wiestler, O.D. and Radner, H. 1994. Pathology of neurofibromatosis 1 and 2. In The neurofibromatoses. A clinical and pathogenetic overview (ed. S.M. Huson and R.A.C. Hughes), pp. 135-159. Chapman & Hall, London, UK.
39. Willis, R.A. 1958. The embryonic tumours and teratomas. In The borderland of embryology and pathology, pp. 410-454. Butterworth and Co., London, UK.
40. Yamauchi, Y., Abe, K., Mantani, A., Hitoshi, Y., Suzuki, M., Osuzu, F., Kuratani, S., and Yamamura, K. 1999. A novel transgenic technique that allows specific marking of the neural crest cell lineage in mice. Dev. Biol. 212: 191-203.
41. Zorick, T.S. and Lemke, G. 1996. Schwann cell differentiation. Curr. Opin. Cell Biol. 8: 870-876.